FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2134277793> ?p ?o ?g. }

• W2134277793 endingPage "229" @default.
• W2134277793 startingPage "224" @default.
• W2134277793 abstract "Abstract Purpose: The study aims to evaluate the efficacy and toxicity of fenretinide in preventing tumor recurrence in patients with transitional cell carcinoma (TCC) of the bladder. Experimental Design: We conducted a multicenter phase III, randomized, placebo-controlled trial of fenretinide (200 mg/day orally for 12 months) in patients with non–muscle-invasive bladder TCC (stages Ta, Tis, or T1) after transurethral resection with or without adjuvant intravesical Bacillus Calmette-Guerin (BCG). Patients received cystoscopic evaluation and bladder cytology every 3 months during the 1-year on study drug and a final evaluation at 15 months. The primary endpoint was time to recurrence. Results: A total of 149 patients were enrolled; 137 were evaluable for recurrence. The risk of recurrence was considered to be “low” in 72% (no prior BCG) and intermediate or high in 32% (prior BCG) of the evaluable patients. Of the lower-risk group, 68% had solitary tumors and 32% had multifocal, low-grade papillary (Ta, grade 1 or grade 2) tumors. The 1-year recurrence rates by Kaplan-Meier estimate were 32.3% (placebo) versus 31.5% (fenretinide; P = 0.88 log-rank test). Fenretinide was well tolerated and had no unexpected toxic effects; only elevated serum triglyceride levels were significantly more frequent on fenretinide (versus placebo). The Data Safety and Monitoring Board recommended study closure at 149 patients (before reaching the accrual goal of 160 patients) because an interim review of the data showed a low likelihood of detecting a difference between the two arms, even if the original accrual goal was met. Conclusions: Although well tolerated, fenretinide did not reduce the time-to-recurrence in patients with Ta, T1, or Tis TCC of the bladder." @default.
• W2134277793 created "2016-06-24" @default.
• W2134277793 creator A5006702120 @default.
• W2134277793 creator A5010529228 @default.
• W2134277793 creator A5011705563 @default.
• W2134277793 creator A5016797027 @default.
• W2134277793 creator A5021979132 @default.
• W2134277793 creator A5024794783 @default.
• W2134277793 creator A5032687039 @default.
• W2134277793 creator A5033068860 @default.
• W2134277793 creator A5034005227 @default.
• W2134277793 creator A5046472038 @default.
• W2134277793 creator A5048604566 @default.
• W2134277793 creator A5055870934 @default.
• W2134277793 creator A5067847839 @default.
• W2134277793 creator A5069190968 @default.
• W2134277793 creator A5071006955 @default.
• W2134277793 creator A5073466977 @default.
• W2134277793 creator A5076525924 @default.
• W2134277793 creator A5082133160 @default.
• W2134277793 creator A5082891764 @default.
• W2134277793 creator A5085172191 @default.
• W2134277793 date "2008-01-01" @default.
• W2134277793 modified "2023-10-03" @default.
• W2134277793 title "Phase III Prevention Trial of Fenretinide in Patients with Resected Non–Muscle-Invasive Bladder Cancer" @default.
• W2134277793 cites W1492826680 @default.
• W2134277793 cites W1525444530 @default.
• W2134277793 cites W172279490 @default.
• W2134277793 cites W1948079440 @default.
• W2134277793 cites W1963592300 @default.
• W2134277793 cites W1990639292 @default.
• W2134277793 cites W1991147663 @default.
• W2134277793 cites W1991725525 @default.
• W2134277793 cites W1999306002 @default.
• W2134277793 cites W2000169972 @default.
• W2134277793 cites W2002045993 @default.
• W2134277793 cites W2006177211 @default.
• W2134277793 cites W2007103166 @default.
• W2134277793 cites W2032287159 @default.
• W2134277793 cites W2032665275 @default.
• W2134277793 cites W2047114154 @default.
• W2134277793 cites W2063668355 @default.
• W2134277793 cites W2065803044 @default.
• W2134277793 cites W2068970085 @default.
• W2134277793 cites W2078932376 @default.
• W2134277793 cites W2093947533 @default.
• W2134277793 cites W2097986356 @default.
• W2134277793 cites W2103602077 @default.
• W2134277793 cites W2105935489 @default.
• W2134277793 cites W2106568960 @default.
• W2134277793 cites W2107988875 @default.
• W2134277793 cites W2109568316 @default.
• W2134277793 cites W2110675408 @default.
• W2134277793 cites W2116722072 @default.
• W2134277793 cites W2117304898 @default.
• W2134277793 cites W2127880200 @default.
• W2134277793 cites W2141354259 @default.
• W2134277793 cites W2154015002 @default.
• W2134277793 cites W2154372376 @default.
• W2134277793 cites W2160462470 @default.
• W2134277793 cites W2226738742 @default.
• W2134277793 cites W2317242858 @default.
• W2134277793 cites W2332357435 @default.
• W2134277793 cites W2399355705 @default.
• W2134277793 cites W2409496467 @default.
• W2134277793 cites W2412180399 @default.
• W2134277793 cites W2416285138 @default.
• W2134277793 cites W4244865023 @default.
• W2134277793 cites W4251697086 @default.
• W2134277793 doi "https://doi.org/10.1158/1078-0432.ccr-07-0733" @default.
• W2134277793 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18172274" @default.
• W2134277793 hasPublicationYear "2008" @default.
• W2134277793 type Work @default.
• W2134277793 sameAs 2134277793 @default.
• W2134277793 citedByCount "59" @default.
• W2134277793 countsByYear W21342777932012 @default.
• W2134277793 countsByYear W21342777932013 @default.
• W2134277793 countsByYear W21342777932014 @default.
• W2134277793 countsByYear W21342777932015 @default.
• W2134277793 countsByYear W21342777932016 @default.
• W2134277793 countsByYear W21342777932017 @default.
• W2134277793 countsByYear W21342777932018 @default.
• W2134277793 countsByYear W21342777932020 @default.
• W2134277793 countsByYear W21342777932021 @default.
• W2134277793 countsByYear W21342777932022 @default.
• W2134277793 countsByYear W21342777932023 @default.
• W2134277793 crossrefType "journal-article" @default.
• W2134277793 hasAuthorship W2134277793A5006702120 @default.
• W2134277793 hasAuthorship W2134277793A5010529228 @default.
• W2134277793 hasAuthorship W2134277793A5011705563 @default.
• W2134277793 hasAuthorship W2134277793A5016797027 @default.
• W2134277793 hasAuthorship W2134277793A5021979132 @default.
• W2134277793 hasAuthorship W2134277793A5024794783 @default.
• W2134277793 hasAuthorship W2134277793A5032687039 @default.
• W2134277793 hasAuthorship W2134277793A5033068860 @default.
• W2134277793 hasAuthorship W2134277793A5034005227 @default.
• W2134277793 hasAuthorship W2134277793A5046472038 @default.
• W2134277793 hasAuthorship W2134277793A5048604566 @default.

• next